Abstract:You have accessJournal of UrologyBladder Cancer: Upper Tract TCC I1 Apr 2015MP2-01 CONTRALATERAL UPPER TRACT UROTHELIAL CARCINOMA AFTER NEPHROURETERECTOMY: THE PREDICTIVE ROLE OF METHYLATION STATUS Lei Zhang, Gengyan Xiong, Dong Fang, Xuesong Li, Jin Liu, Weimin Ci, Wei Zhao, Nirmish Singla, Zhisong He, and Li Zhou Lei ZhangLei Zhang More articles by this author , Gengyan XiongGengyan Xiong More articles by this author , Dong FangDong Fang More articles by this author , Xuesong LiXuesong Li More articles by this author , Jin LiuJin Liu More articles by this author , Weimin CiWeimin Ci More articles by this author , Wei ZhaoWei Zhao More articles by this author , Nirmish SinglaNirmish Singla More articles by this author , Zhisong HeZhisong He More articles by this author , and Li ZhouLi Zhou More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.124AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Aberrant methylation of genes is one of the most common epigenetic modifications involved in the development of urothelial carcinoma. However, it is unknown that the predictive role of methylation to contralateral new upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). To evaluate the role of gene methylation in predicting contralateral UTUC recurrence after RNU. METHODS In a retrospective design, methylation of 10 genes was analyzed on tumor specimens belonging to 664 consecutive patients treated by RNU for primary UTUC. Median follow-up was 48 mo (range: 3–144 mo). Gene methylation was accessed by methylation-sensitive polymerase chain reaction, and we calculated the methylation index (MI), a reflection of the extent of methylation. The log-rank test and Cox regression were used to identify the predictor of contralateral UTUC recurrence. RESULTS Promoter methylation was present in 88.9% of UTUC. Fewer methylation and lower MI (P=0.001) were seen in the tumors with contralateral UTUC recurrence than the tumors without contralateral recurrence. High MI (P=0.007) was significantly correlated with poor cancer-specific survival. Multivariate analysis indicated that unmethylated RASSF1A (P=0.039), lack of bladder recurrence prior to contralateral UTUC (P=0.009), history of renal transplantation (P<0.001), and preoperative renal insufficiency (P=0.002) are independent risk factors for contralateral UTUC recurrence after RNU. CONCLUSIONS Methylation is frequent in UTUCs generally, and relative infrequent in tumors with contralateral UTUC recurrence. Methylation is a new promising predictor of contralateral UTUC recurrence after RNU. Table 3. MI based on the clinicopathological factors. No. of patients MI P Mean SD Grade <0.001* G1 21 0.1667 0.14606 G2 360 0.3161 0.22121 G3 283 0.3594 0.23732 Stage <0.001* Ta or T1 221 0.3009 0.21062 T2 237 0.2975 0.21803 T3 194 0.3964 0.24629 T4 12 0.4250 0.24541 N status 0.014* cN0 or pNo 617 0.3241 0.22860 N+ 47 0.4043 0.22259 Architecture 0.001* Papillary 515 0.3140 0.22534 Sessile 149 0.3846 0.23358 Ipsilateral hydronephrosis 0.015* Absence 290 0.3545 0.23248 Presence 374 0.3107 0.22461 Main tumor location 0.000* Pelvic 368 0.3677 0.23324 Upper ureter 58 0.2914 0.22027 Middle ureter 68 0.2824 0.21644 Lower ureter 170 0.2800 0.21334 Transplant recipient 0.011* No 653 0.3326 0.22861 Yes 11 0.1636 0.19117 MI=methylation index. Table 1. Patient demographic and histological data. Variables N (%) Gender Male 295 (44.4) Female 369 (55.6) Age <70 372 (56.0) ≥70 292 (44.0) Preoperative renal function eGFR≥60 298 (44.9) 60＞eGFR≥30 316 (47.6) eGFR＜30 50 (7.5) Side Left 326 (49.1) Right 338 (50.9) Transplant recipient No 653 (98.3) Yes 11 (1.7) Ipsilateral hydronephrosis Absence 290 (43.7) Presence 374 (56.3) Tobacco consumption No 543 (81.8) Yes 121 (18.2) Surgical approach Open 445 (67.0) Laparoscopic 219 (33.0) Tumor size ≤3cm 373 (56.2) ＞3cm 291 (43.8) Architecture Papillary 515 (77.6) Sessile 149 (22.4) Ureteroscopy No 583 (87.8) Yes 81 (12.2) Location Pelvis 368 (55.4) Ureter ureter 296 (44.6) Upper ureter 58 (8.7) Middle ureter 68 (10.2) Lower ureter 170 (25.6) Multifocality No 505 (76.1) Yes 159 (23.9) CIS Absence 645 (97.1) Presence 19 (2.9) Contralateral recurrence No 634 (95.5) Yes 30 (4.5) Bladder recurrence No 441 (66.4) Yes 223 (33.6) Before contralateral UTUC 209 (31.5) Concomitant and after contralateral UTUC 14 (2.1) Tumor stage Ta or T1 221 (33.3) T2 237 (35.7) T3 194 (29.2) T4 12 (1.8) Tumor grade G1 21 (3.2) G2 360 (54.2) G3 283 (42.6) N status N+ 47 (7.1) cN0 or pN0 617 (92.9) Adjuvant therapy No 641 (96.5) Yes 23 (3.5) eGFR=estimated glomerular filtration rate; CIS=carcinoma in situ; UTUC=upper tract urothelial carcinoma. Table 4. Predictive factors for contralateral UTUC recurrence after RNU Variable Univariate Multivariate Chi-square P HR 95% CI P Gender 2.051 0.152 Age 2.256 0.112 Renal function 27.746 <0.001* 0.418 0.242-0.723 0.002* Side 0.140 0.708 Transplant recipient 74.902 <0.001* 20.914 8.208-53.284 <0.001* Ipsilateral hydronephrosis 1.367 0.242 Smoke 0.063 0.802 Surgical approach 1.891 0.169 Tumor size 0.817 0.366 Architecture 0.737 0.391 Ureteroscopy 0.828 0.363 Location 2.015 0.569 Mulifocality 0.536 0.464 CIS 0.899 0.343 Bladder recurrencea 4.612 0.032* 0.258 0.097-0.691 0.007* Tumor stage 1.104 0.776 Tumor grade 1.730 0.421 N status 0.230 0.631 Adjuvant therapy 0.015 0.902 ABCC6 1.963 0.161 BRCA1 0.226 0.634 CDH1 2.226 0.136 GDF15 1.077 0.299 HSPA2 0.084 0.772 RASSF1A 5.481 0.019* 0.218 0.051-0.927 0.039* SALL3 1.696 0.193 THBS1 2.971 0.085 TMEFF2 1.072 0.301 VIM 5.004 0.025* 0.278 MI 3.918 0.048* -b CIS=carcinoma in situ; MI=methylation index. a Only bladder recurrence before contralateral UTUC recurrence was analyzed. b Because the MI correlated with methylation status of RASSF1A (r=0.412, P=0.000) and VIM (r=0.478, P=0.000), the MI was not analyzed in the multivariate models. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e9-e10 Peer Review Report Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Lei Zhang More articles by this author Gengyan Xiong More articles by this author Dong Fang More articles by this author Xuesong Li More articles by this author Jin Liu More articles by this author Weimin Ci More articles by this author Wei Zhao More articles by this author Nirmish Singla More articles by this author Zhisong He More articles by this author Li Zhou More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

MP27-03 HYPERMETHYLATION OF THE RASSF1A GENE PROMOTER AT CYTOSINE GUANINE DINUCLEOTIDE ISLANDS PREDICTS HIGHER MALIGNANT POTENTIAL BUT BETTER URINARY TRACT RECURRENCE-FREE SURVIVAL IN UPPER TRACT UROTHELIAL CARCINOMA PATIENTS AFTER SURGERY

MP2-03 PROGNOSTIC AND PREDICTIVE VALUE OF EPIGENETIC BIOMARKERS IN UPPER TRACT UROTHELIAL CARCINOMA

MP2-01 CONTRALATERAL UPPER TRACT UROTHELIAL CARCINOMA AFTER NEPHROURETERECTOMY: THE PREDICTIVE ROLE OF METHYLATION STATUS

A Novel DNA Methylation Signature As an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer

[Methylation status of RASSF1A gene promoter in upper tract urothelial carcinoma and its clinical significance].

Prognostic and Predictive Value of Epigenetic Biomarkers and Clinical Factors in Upper Tract Urothelial Carcinoma

Predictive Value of Gene Methylation for Second Recurrence Following Surgical Treatment of First Bladder Recurrence of a Primary Upper-Tract Urothelial Carcinoma.

MP27-04 HOMOGENOUS OR HETEROGENOUS BIOLOGICAL BEHAVIORS BETWEEN URETERAL AND RENAL PELVIC TUMORS? A COMPARISON OF CLINICAL FEATURES, PATHOLOGICAL OUTCOMES, EPIGENETIC BIOMARKERS AND ONCOLOGIC PROGNOSIS

Prognostic Value of Gene Methylation and Clinical Factors in Non–Muscle-Invasive Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy

Integrated Analysis Reveals Molecular Features of Upper Tract Urothelial Carcinoma and Prognostic Value of Neutrophil Infiltration for Adjuvant Chemotherapy

MP2-02 HIGH EXPRESSION OF KARYOPHERIN α2 DEFINES POOR PROGNOSIS IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA TREATED WITH RADICAL NEPHROURETERECTOMY

MP45-14 EPIGENETIC REGULATION OF CANDIDATE TUMOR SUPPRESSOR GENE ADAMTS18 IN HUMAN BLADDER CANCER ASSOCIATED WITH ITS PROGNOSIS

Contralateral Upper Tract Urothelial Carcinoma after Nephroureterectomy: the Predictive Role of DNA Methylation

The Association Of Ras Association Domain Family Protein1a (Rassf1a) Methylation States And Bladder Cancer Risk: A Systematic Review And Meta-Analysis

AB162. Prognostic and predictive value of epigenetic biomarkers and clinical factors in upper tract urothelial carcinoma

Mp85-14 aberrant methylation of ccnd2 is associated with loss of expression and tumor pathylogical subtypes in renal cell cancer

DNA Methylation Architecture Provides Insight into the Pathogenesis of Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-Analysis

MP47-08 THE METHYLATION OF SOX7 AND ITS FUNCTION AS A TUMOR SUPPRESSOR IN RENAL CELL CANCER

MP55-10 EPIGENETIC REGULATION OF THE 3P22 TUMOR SUPPRESSOR DLEC1 IN HUMAN PROSTATE CANCER ASSOCIATED WITH ITS PROGNOSIS

Comparison of Clinicopathologic Characteristics, Epigenetic Biomarkers and Prognosis Between Renal Pelvic and Ureteral Tumors in Upper Tract Urothelial Carcinoma.

The expression of RASSF1A protein and promoter hypermethylation of RASSF1A gene in bladder transitional cell carcinoma